- Forum provides platform for discussion on current and future care
of patients living with Gaucher disease -
Company Website:
http://www.genzyme.com
CAMBRIDGE, Mass. -- (Business Wire)
Genzyme,
a Sanofi company, today announced that the sixth annual Gaucher
Leadership Forum (GLF) will take place on March 27 and 28 in Berlin,
Germany.
The GLF is a scientific meeting sponsored by Genzyme that brings
together approximately 200 participants from around the world, including
physicians, academics, researchers and patient organization
representatives to discuss current care for patients with Gaucher
disease and the direction of future disease management. This year’s GLF
will be chaired by Timothy M. Cox, Professor of Medicine at the
University of Cambridge. The theme for 2015 is: “New Clinical Science
of Gaucher Disease” and will focus on the following objectives:
-
Advancing therapeutics through greater understanding of pathogenesis
(molecular & otherwise)
-
Fostering collaborative and interdisciplinary research
-
Inspiring (recruiting) the next generation of clinician researchers
and scientists
“In designing this year’s GLF program, we have sought to encompass the
hugely diverse aspects of Gaucher disease as they impinge on the lives
and well-being of patients all over the world. It is chastening to
realize that despite radical improvements over the last 25 years, many
aspects of this condition remain very hard to treat; and even when the
diagnosis eventually has come to light, not every patient can gain
access to the best standards of care,” said Prof. Cox. “This meeting
will give time for open sharing of experience and seeks to explore
under-recognized aspects of the disease that are often neglected in the
heat of routine practice.”
The opening plenary session will highlight the most recent scientific
discoveries in the field of Gaucher disease research. Additionally,
several interactive working groups have been established to focus on:
(1) Spectrum of Clinical Manifestations in Gaucher Disease; (2) Gaucher
Disease Type 3: Addressing Patients’ and Families’ Concerns; (3) Unmet
Needs in the Assessment of Bone Disease in Gaucher; and (4) Gaucher
Disease and Cancer: Mechanisms and Management.
“The GLF is an excellent example of global collaboration and
partnership, with the Gaucher community working together to propel
research forward and further our understanding of Gaucher disease,” said
Genzyme’s Acting Head of Rare Diseases, Richard Peters, MD, Ph.D. “While
much progress has been made, great need still exists, particularly
around the neuronopathic forms of Gaucher disease. We look forward to
lively discussion while we work to achieve our collective goal to
support the needs of the global Gaucher community.”
About Genzyme, a Sanofi Company
Genzyme has pioneered the development and delivery of transformative
therapies for patients affected by rare and debilitating diseases for
over 30 years. We accomplish our goals through world-class research and
with the compassion and commitment of our employees. With a focus on
rare diseases and multiple sclerosis, we are dedicated to making a
positive impact on the lives of the patients and families we serve. That
goal guides and inspires us every day. Genzyme’s portfolio of
transformative therapies, which are marketed in countries around the
world, represents groundbreaking and life-saving advances in medicine.
As a Sanofi company, Genzyme benefits from the reach and resources of
one of the world’s largest pharmaceutical companies, with a shared
commitment to improving the lives of patients. Learn more at www.genzyme.com.
Genzyme® is a registered trademark of Genzyme Corporation.
All rights reserved.
About Sanofi
Sanofi, a global and diversified healthcare leader, discovers, develops
and distributes therapeutic solutions focused on patients’ needs. Sanofi
has core strengths in the field of healthcare with seven growth
platforms: diabetes solutions, human vaccines, innovative drugs,
consumer healthcare, emerging markets, animal health and Genzyme.
Sanofi Forward-Looking Statements
This press release contains forward-looking statements as defined in
the Private Securities Litigation Reform Act of 1995, as amended.
Forward-looking statements are statements that are not historical facts.
These statements include projections and estimates and their underlying
assumptions, statements regarding plans, objectives, intentions and
expectations with respect to future financial results, events,
operations, services, product development and potential, and statements
regarding future performance. Forward-looking statements are generally
identified by the words "expects", "anticipates", "believes", "intends",
"estimates", "plans" and similar expressions. Although Sanofi's
management believes that the expectations reflected in such
forward-looking statements are reasonable, investors are cautioned that
forward-looking information and statements are subject to various risks
and uncertainties, many of which are difficult to predict and generally
beyond the control of Sanofi, that could cause actual results and
developments to differ materially from those expressed in, or implied or
projected by, the forward-looking information and statements. These
risks and uncertainties include among other things, the uncertainties
inherent in research and development, future clinical data and analysis,
including post marketing, decisions by regulatory authorities, such as
the FDA or the EMA, regarding whether and when to approve any drug,
device or biological application that may be filed for any such product
candidates as well as their decisions regarding labelling and other
matters that could affect the availability or commercial potential of
such product candidates, the absence of guarantee that the product
candidates if approved will be commercially successful, the future
approval and commercial success of therapeutic alternatives, the Group's
ability to benefit from external growth opportunities, trends in
exchange rates and prevailing interest rates, the impact of cost
containment policies and subsequent changes thereto, the average number
of shares outstanding as well as those discussed or identified in the
public filings with the SEC and the AMF made by Sanofi, including those
listed under "Risk Factors" and "Cautionary Statement Regarding
Forward-Looking Statements" in Sanofi's annual report on Form 20-F for
the year ended December 31, 2014. Other than as required by applicable
law, Sanofi does not undertake any obligation to update or revise any
forward-looking information or statements.
Contacts:
Media Contact:
Genzyme
Lori
Gorski, 617-768-9344
Lori.Gorski@genzyme.com
Source: Genzyme Corporation
© 2024 Canjex Publishing Ltd. All rights reserved.